ArticleTranslational cancer research2020
MTA1 is an indicator of prognosis in Chinese patients with lung adenocarcinoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe predictive role of metastatic tumor antigen 1 (MTA1) expression in lung cancer (LC) is still uncertain. This meta-analysis was performed to clarify the relationship of MTA1 protein expression with the prognosis of LC.
methodsThe PubMed and CNKI databases were searched for clinical studies demonstrating the expression of MTA1 in LC for further review.
resultsA total of ten studies comprising 982 patients were included in the meta-analysis according to the predefined selection criteria. Our results indicated that MTA1 overexpression had a significant impact on progression-free survival (PFS) (HR 2.16; 95% CI, 1.62-2.89) and OS (HR 2.38; 95% CI, 1.78-3.19). Heterogeneity was observed (I
conclusionsA high level of MTA1 expression predicts poor survival in Chinese patients with lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.